Back

Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy

2 September 2024 (15:39 - 15:51)
Organised by: Logo
Congress Presentation Part of: Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies Oral Anticoagulation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Renate B Schnabel

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

4 More presentations in this session

Presentation thumbnail
Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71
Doctor S. Patel (Boston, US)
Slides Video
Presentation thumbnail
Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial
Doctor N. Uriel (New York, US)
Slides Video
Presentation thumbnail
The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial
Associate Professor M. Proietti (Milan, IT)
Slides Video
Presentation thumbnail
Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial
Doctor L. Rivard (Montreal, CA)
Video

Access the full session

Session thumbnail
Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 15:39 CET
You may be interested in
thumbnail
Congress Presentation
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies
thumbnail
Congress Presentation
Device-detected atrial fibrillation: does thromboembolic risk affect decision-making on anticoagulation management?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources